Good job_老虎社区_美港股上老虎

Yongstonio
2021-06-30

Good job

Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab

SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore

Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":153242479,"tweetId":"153242479","gmtCreate":1625029920491,"gmtModify":1631891737983,"author":{"id":3569913551788820,"authorId":3569913551788820,"authorIdStr":"3569913551788820","name":"Yongstonio","avatar":"https://static.tigerbbs.com/416ee5e99c5bc9b5db9e020ff2af415b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good job</p></body></html>","htmlText":"<html><head></head><body><p>Good job</p></body></html>","text":"Good job","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/153242479","repostId":2147689312,"repostType":4,"repost":{"id":"2147689312","pubTimestamp":1625015157,"share":"https://www.laohu8.com/m/news/2147689312?lang=&edition=full","pubTime":"2021-06-30 09:05","market":"us","language":"en","title":"Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2147689312","media":"The Straits Times","summary":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore","content":"<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore inks deal with GSK to purchase Covid-19 drug sotrovimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 09:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients ...</p>\n\n<a href=\"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"source_url":"http://www.straitstimes.com/singapore/health/singapore-inks-deal-with-gsk-to-purchase-covid-19-drug-sotrovimab","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2147689312","content_text":"SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients with mild to moderate Covid-19.\nThe advance purchase agreement is for the supply of sotrovimab, an investigational single-dose monoclonal antibody administered through intravenous infusion, GSK Singapore said in a statement on Wednesday (June 29).\nIt is used to treat Covid-19 patients who do not need supplemental oxygen but are at risk of progressing to severe disease.\nSotrovimab is currently undergoing regulatory review by the Health Sciences Authority for interim authorisation under the Pandemic Special Access Route (PSAR), GSK Singapore said.\nThe medication was, on May 26, granted emergency-use authorisation by the United States Food and Drug Administration; the European Medicines Agency's Committee for Medicinal Products for Human Use has also issued a positive scientific opinion.\nThe British drugmaker's PSAR application includes data from an interim analysis of efficacy and safety data from its phase three trial, which it said was stopped early by an independent data-monitoring committee in March due to evidence of \"profound clinical efficacy\".\n\"Results of the interim analysis, based on data from 583 randomised patients, demonstrated an 85 per cent reduction in hospitalisation or death in those receiving sotrovimab compared to placebo, the primary endpoint of the trial,\" GSK Singapore said.\nIt noted that the PSAR review will also consider the medicine's quality and safety data, adding that final results from its efficacy trial will be available later this year.\nPreclinical data has suggested that sotromivab targets a conserved epitope of the Sars-CoV-2 spike protein, which is less likely to mutate over time, GSK said.\nDr Phil Pang, chief medical officer of Vir, said the treatment appears to \"retain activity against all circulating variants of concern\", including the highly transmissible Delta variant which originated from India, based on data from several in vitro studies.\nMr Mike Crichton, senior vice-president for speciality and primary-care therapy area at GSK, said vaccines, together with treatments like sotrovimab, have the potential to increase the chance of ending the pandemic, as variants of the coronavirus continue to arise.\nGSK and Vir are in discussions with other governments to explore similar supply agreements, as countries accelerate their vaccine and therapeutics programmes against Covid-19, the company said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":16,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}